• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

应用皮质类固醇和来迪派韦-索磷布韦治疗丙型肝炎病毒感染相关的膜性肾病：一例报告并文献复习

Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature.

作者信息

Weng Qinjie, Li Xiao, Ren Hong, Xie Jingyuan, Pan Xiaoxia, Xu Jing, Chen Nan

机构信息

Department of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

出版信息

Oncotarget. 2017 Mar 28;8(13):22299-22303. doi: 10.18632/oncotarget.15397.

DOI:10.18632/oncotarget.15397
PMID:28223549
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5400664/
Abstract

BACKGROUND

Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in adults. As many clinical cases have reported, it may be associated with hepatitis C virus (HCV) infection. Antiviral therapy can be various.

CASE SUMMARY

We report a case of patient with chronic HCV infection and MN, who presented with was proteinuria. He was treated with ledipasvir and sofosbuvir (Harvoni; Gilead Sciences, Foster City, CA) and was found to be virus-free.

CONCLUSION

We have reported this case to provide insight into whether Ledipasvir-Sofosbuvir should be administered for HCV-related glomerulonephritis.

摘要

背景

膜性肾病（MN）是成人肾病综合征最常见的病因。正如许多临床病例报道的那样，它可能与丙型肝炎病毒（HCV）感染有关。抗病毒治疗方法多种多样。

病例摘要

我们报告一例慢性HCV感染合并MN的患者，该患者表现为蛋白尿。他接受了来迪派韦和索磷布韦（Harvoni；吉利德科学公司，加利福尼亚州福斯特城）治疗，结果病毒检测呈阴性。

结论

我们报告此病例是为了深入了解是否应使用来迪派韦-索磷布韦治疗HCV相关性肾小球肾炎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61df/5400664/93ad0f842c8b/oncotarget-08-22299-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61df/5400664/8232af69b244/oncotarget-08-22299-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61df/5400664/93ad0f842c8b/oncotarget-08-22299-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61df/5400664/8232af69b244/oncotarget-08-22299-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61df/5400664/93ad0f842c8b/oncotarget-08-22299-g002.jpg

相似文献

1
Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature.应用皮质类固醇和来迪派韦-索磷布韦治疗丙型肝炎病毒感染相关的膜性肾病：一例报告并文献复习
Oncotarget. 2017 Mar 28;8(13):22299-22303. doi: 10.18632/oncotarget.15397.
2
Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual.治愈历史上无法治愈的疾病：对于一名经历过多次治疗的个体，使用来迪派韦/索磷布韦治疗慢性丙型肝炎病毒获得成功。
J Clin Pharm Ther. 2016 Dec;41(6):727-729. doi: 10.1111/jcpt.12455. Epub 2016 Sep 27.
3
Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.索磷布韦维帕他韦治疗 5 型丙型肝炎病毒感染患者：一项开放标签、多中心、单臂、2 期研究。
Lancet Infect Dis. 2016 Apr;16(4):459-64. doi: 10.1016/S1473-3099(15)00529-0. Epub 2016 Jan 21.
4
Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.利巴韦林联合或不联合 ledipasvir 和 sofosbuvir 治疗 12 周治疗 HCV 基因型 3 或 6 感染患者的疗效。
Gastroenterology. 2015 Nov;149(6):1454-1461.e1. doi: 10.1053/j.gastro.2015.07.063. Epub 2015 Aug 7.
5
Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.三名患者在肝移植后接受索磷布韦加来迪帕司韦治疗复发性丙型肝炎。
Clin J Gastroenterol. 2017 Apr;10(2):179-184. doi: 10.1007/s12328-017-0722-7. Epub 2017 Feb 21.
6
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.来迪派韦索磷布韦片与索磷布韦联用治疗初治的 HCV 基因 1 型感染。
N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.
7
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).来迪派韦索磷布韦联合或不联合利巴韦林治疗对既往蛋白酶抑制剂治疗无应答的 HCV 基因 1 型感染合并肝硬化患者：一项随机、双盲、II 期临床试验（SIRIUS）
Lancet Infect Dis. 2015 Apr;15(4):397-404. doi: 10.1016/S1473-3099(15)70050-2. Epub 2015 Mar 13.
8
Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.来迪派韦+索磷布韦（哈瓦尼）。尽管存在不确定性，但在1型丙型肝炎病毒感染的治疗上取得了进展。
Prescrire Int. 2015 Dec;24(166):285-9.
9
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.聚乙二醇干扰素α-2a 联合利巴韦林治疗慢性丙型肝炎
N Engl J Med. 2014 May 15;370(20):1879-88. doi: 10.1056/NEJMoa1402355. Epub 2014 Apr 10.
10
Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.雷迪帕韦/索磷布韦：用于慢性丙型肝炎的综述。
Drugs. 2015 Apr;75(6):675-85. doi: 10.1007/s40265-015-0381-2.

引用本文的文献

1
Membranous Nephropathy.膜性肾病
J Clin Med. 2025 Jan 24;14(3):761. doi: 10.3390/jcm14030761.
2
How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy.时代变了！膜性肾病的抗原宝库。
Front Immunol. 2021 Nov 26;12:800242. doi: 10.3389/fimmu.2021.800242. eCollection 2021.
3
Secondary Membranous Nephropathy. A Narrative Review.继发性膜性肾病。一篇综述。

本文引用的文献

1
Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C.来迪派韦/索磷布韦固定剂量复方片剂治疗丙型肝炎的临床药代动力学和药效学
Clin Pharmacokinet. 2016 Nov;55(11):1337-1351. doi: 10.1007/s40262-016-0397-0.
2
Harvoni (Ledipasvir With Sofosbuvir)-Induced Renal Injury.哈瓦尼（来迪派韦与索非布韦联用）所致肾损伤。
Am J Gastroenterol. 2016 Jan;111(1):148-9. doi: 10.1038/ajg.2015.391.
3
Treatment of hepatitis C-related kidney disease.丙型肝炎相关肾脏疾病的治疗。
Front Med (Lausanne). 2020 Dec 3;7:611317. doi: 10.3389/fmed.2020.611317. eCollection 2020.
4
Remission of long-term hepatic and renal disease induced by HCV after direct-acting antivirals therapy.直接作用抗病毒药物治疗后 HCV 引起的长期肝和肾疾病的缓解。
J Bras Nefrol. 2021 Jan-Mar;43(1):117-120. doi: 10.1590/2175-8239-JBN-2019-0165.
5
Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management.膜性肾病与抗足细胞抗体：对诊断和疾病管理的影响。
Biomed Res Int. 2018 Jan 8;2018:6281054. doi: 10.1155/2018/6281054. eCollection 2018.
Expert Opin Pharmacother. 2015;16(12):1815-27. doi: 10.1517/14656566.2015.1066333. Epub 2015 Jul 10.
4
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.丙型肝炎指南：美国肝病研究学会-美国感染病学会关于丙型肝炎病毒感染成人检测、管理及治疗的建议
Hepatology. 2015 Sep;62(3):932-54. doi: 10.1002/hep.27950. Epub 2015 Aug 4.
5
A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan.中国、日本、韩国及台湾地区丙型肝炎病毒感染负担综述。
Hepatol Int. 2015 Jul;9(3):378-90. doi: 10.1007/s12072-015-9629-x. Epub 2015 Jun 13.
6
Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.索磷布韦和来迪帕司韦治疗丙型肝炎的安全性分析
Expert Opin Drug Saf. 2015 Aug;14(8):1317-26. doi: 10.1517/14740338.2015.1053868. Epub 2015 Jun 4.
7
Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection.来迪派韦/索磷布韦（哈瓦尼）：改善丙型肝炎病毒感染的治疗选择
P T. 2015 Apr;40(4):256-76.
8
Management of patients with hepatitis C infection and renal disease.丙型肝炎感染合并肾脏疾病患者的管理。
World J Hepatol. 2015 Feb 27;7(2):213-25. doi: 10.4254/wjh.v7.i2.213.
9
Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C.
Expert Opin Pharmacother. 2015 Apr;16(6):801-4. doi: 10.1517/14656566.2015.1019862. Epub 2015 Mar 1.
10
Hepatitis C virus associated glomerulopathies.丙型肝炎病毒相关性肾小球病
World J Gastroenterol. 2014 Jun 28;20(24):7544-54. doi: 10.3748/wjg.v20.i24.7544.